Active Filter(s):
Details:
The CHPM opinion is based on a trial (study 017) in which Cenobamate demonstrated significantly higher responder rates (percentage of patients achieving ≥50% reduction in seizures frequency) across all doses during the 12-week maintenance phase compared to placebo.
Lead Product(s): Cenobamate
Therapeutic Area: Neurology Product Name: Ontozry
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: SK Biopharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 29, 2021
Details:
Following Angelini Pharma’s acquisition of Arvelle Therapeutics, Angelini Pharma will have the exclusive license to commercialize cenobamate in the European Union and other countries in the European Economic Area (Switzerland and the United Kingdom).
Lead Product(s): Cenobamate
Therapeutic Area: Neurology Product Name: Xcopri
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Angelini Pharma
Deal Size: $960.0 million Upfront Cash: $960.0 million
Deal Type: Acquisition January 04, 2021
Details:
The final tranche was triggered by the European Medicines Agency’s (EMA) recent acceptance of the marketing authorization application (MAA) for cenobamate for the adjunctive treatment of focal-onset seizures in adults with epilepsy, announced on 26 March 2020.
Lead Product(s): Cenobamate
Therapeutic Area: Neurology Product Name: Xcopri
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: European Medicines Agency
Deal Size: $207.8 million Upfront Cash: Undisclosed
Deal Type: Series A Financing October 26, 2020
Details:
UK’s Medicines and Healthcare Products Regulatory Agency has informed Cenobamate that a Promising Innovative Medicine designation has been issued for its investigational anti-seizure medication, cenobamate, for the treatment of drug-resistant focal-onset seizures in adults.
Lead Product(s): Cenobamate
Therapeutic Area: Neurology Product Name: Xcopri
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 11, 2020
Details:
28% of patients receiving cenobamate achieved seizure-freedom (zero seizures) during the study’s maintenance phase, versus 9% receiving placebo1.
Lead Product(s): Cenobamate
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 21, 2020